

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)  PTO Form 1449	Atty Docket No. 116566-002	Application No. 10/526,127
	Applicant Campochiaro et al.	
	Filing Date 28 February 2005	Group Unassigned

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	6,267,954	7/31/01	Abitbol et al.			

FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 0193097	12/13/01	WIPO				
	WO 0230982	4/18/02	WIPO				

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Mori, Kei-uke et al., "Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secreted endostatin," <i>American Journal of Pathology</i> , Vol. 159, No. 1, July 2001, pp. 313-326.
	Ohno-Matsui, Kyoko et al., "Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment," <i>American Journal of Pathology</i> , Vol. 168, No. 2, February 2002, pp. 711-719.
	Ozaki, H. et al., "Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization," <i>American Journal of Pathology</i> , Vol. 156, No. 2, February 2000, pp. 697-707.
	Takahashi, Kyoichi et al., "Intracocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment," <i>FASEB Journal</i> , Vol. 17, No. 8, May 2003, pp. 896-898.

Examiner: /Scott Long/ (02/24/2009)	Date Considered: 02/24/2009
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	